CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB1293 : SSP-25]

22904 Yang YSH, Tsai CC, Yang YN, Liu FC, Lee SY, Yang JC, Crawford DR, Chiu HC, Lu MC, Li ZL, Chen YC, Chu TY, Whang-Peng J, Lin HY, Wang K. Heteronemin suppresses EGF‑induced proliferation through the PI3K/PD‑L1 signaling pathways in cholangiocarcinoma Oncol Rep 2025 53(3):32 PubMed ID: 39791224 DOI: 10.3892/or.2025.8865

21829 Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science 2024 385(6705):eadl6173 PubMed ID: 38991060 DOI: 10.1126/science.adl6173

21886 Schüler J, Vockerodt M, Salehzadeh N, Becker J, Wilting J. Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis. Curr Issues Mol Biol 2024 46(7):7395-7410 PubMed ID: 39057080 DOI: 10.3390/cimb46070439

22487 Kito Y, Kachi K, Yoshida M, Hori Y, Kato A, Sahashi H, Toyohara T, Kuno K, Adachi A, Urakabe K, Kataoka H. Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression Molecules 2024 29(14):3379. PubMed ID: 39064957 DOI: 10.3390/molecules29143379

22503 Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland JA 3rd, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LN. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon JCI Insight 2024 9(2):e174220 PubMed ID: 38060314 DOI: 10.1172/jci.insight.174220

21103 Shi L, Shen W, Davis MI, Kong K, Vu P, Saha SK, Adil R, Kreuzer J, Egan R, Lee TD, Greninger P, Shrimp JH, Zhao W, Wei TY, Zhou M, Eccleston J, Sussman J, Manocha U, Weerasekara V, Kondo H, Vijay V, Wu MJ, Kearney SE, Ho J, McClanaghan J, Murchie E, Crowther GS, Patnaik S, Boxer MB, Shen M, Ting DT, Kim WY, Stanger BZ, Deshpande V, Ferrone CR, Benes CH, Haas W, Hall MD, Bardeesy N. SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers. Nat Cancer 2023 PubMed ID: 36914816 DOI: 10.1038/s43018-023-00523-0

21205 Mohan A, Griffith KA, Wuchu F, Zhen DB, Kumar-Sinha C, Crysler O, Hsiehchen D, Enzler T, Dippman D, Gunchick V, Achreja A, Animasahun O, Choppara S, Nenwani M, Chinnaiyan AM, Nagrath D, Zalupski MM, Sahai V. Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04). Clin Cancer Res 2023 PubMed ID: 37115501 DOI: 10.1158/1078-0432.CCR-23-0036

21288 Pan YR, Wu CE, Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH, Hung TH, Yu AL, Huang WK, Yeh CN. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation. Int J Biol Sci 2023 19(9)2772-2786 PubMed ID: 37324940 DOI: 10.7150/ijbs.79126

21390 Chen CP, Yeh CN, Pan YR, Huang WK, Hsiao YT, Lo CH, Wu CE. Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. Biomed Pharmacother 2023 166:115389 PubMed ID: 37659202 DOI: 10.1016/j.biopha.2023.115389

21456 Toshida K, Itoh S, Iseda N, Izumi T, Yoshiya S, Toshima T, Ninomiya M, Iwasaki T, Oda Y, Yoshizumi T. Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma. Cancer Sci 2023 PubMed ID: 37878531 DOI: 10.1111/cas.15981

20420 Chui NN, Cheu JW, Yuen VW, Chiu DK, Goh CC, Lee D, Zhang MS, Ng IO, Wong CC. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. Hepatol Commun 2022 PubMed ID: 34558800 DOI: 10.1002/hep4.1682

20893 Jamnongsong S, Kueanjinda P, Buraphat P, Sakornsakolpat P, Vaeteewoottacharn K, Okada S, Jirawatnotai S, Sampattavanich S. Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma. iScience 2022 25(10):105182 PubMed ID: 36248745 DOI: 10.1016/j.isci.2022.105182

21148 Kosai-Fujimoto Y, Itoh S, Yugawa K, Fukuhara T, Okuzaki D, Toshima T, Harada N, Oda Y, Yoshizumi T, Mori M. Impact of JMJD6 on intrahepatic cholangiocarcinoma. Mol Clin Oncol 2022 17(2):131 PubMed ID: 35911665 DOI: 10.3892/mco.2022.2564

22891 Sahashi H, Kato A, Yoshida M, Hayashi K, Naitoh I, Hori Y, Natsume M, Jinno N, Kachi K, Asano G, Toyohara T, Kito Y, Ammanamanchi S, Kataoka H. Urolithin A targets the AKT/WNK1 axis to induce autophagy and exert anti-tumor effects in cholangiocarcinoma Front Oncol 2022 12:963314 PubMed ID: 36212467 DOI: 10.3389/fonc.2022.963314

13539 Nagaoka K, Ogawa K, Ji C, Cao KY, Bai X, Mulla J, Cheng Z, Wands JR, Huang CK. Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis Dig Dis Sci 2021 66(4):1080-1089 PubMed ID: 32445050 DOI: 10.1007/s10620-020-06330-2

14929 Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, Fujimoto M, Uemura S, Namikawa T, Murakami I, Kobayashi S, Eguchi H, Doki Y, Hanazaki K, Naka T. Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1 positive cholangiocarcinoma Mol Cancer Ther 2021 molcanther.0015.2021 PubMed ID: 34224365 DOI: 10.1158/1535-7163.MCT-21-0015

15502 Weng SW, Liu TT, Eng HL, You HL, Huang WT. Autophagy Plays a Role in the CUL4A-Related Poor Prognosis of Intrahepatic Cholangiocarcinoma Pathol Oncol Res 2021 27:602714 PubMed ID: 34257560 DOI: 10.3389/pore.2021.602714

12014 Somchai P, Phongkitkarun K, Kueanjinda P, Jamnongsong S, Vaeteewoottacharn K, Luvira V, Okada S, Jirawatnotai S, Sampattavanich S. Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors. Sci Rep 2020 PubMed ID: 31969633 DOI: 10.1038/s41598-020-57806-0

13336 Pan YR, Wu CE, Yeh CN. ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner. Biomolecules 2020 PubMed ID: 33182492 DOI: 10.3390/biom10111529

12588 Yoh T, Hatano E, Kasai Y, Fuji H, Nishi K, Toriguchi K, Sueoka H, Ohno M, Seo S, Iwaisako K, Taura K, Yamaguchi R, Kurokawa M, Fujimoto J, Kimura T, Uemoto S, Nishi E. Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection Clin Cancer Res 2019 25(2):619-628 PubMed ID: 30352908 DOI: 10.1158/1078-0432.CCR-18-0124

12589 Miyata T, Yamashita YI, Yoshizumi T, Shiraishi M, Ohta M, Eguchi S, Aishima S, Fujioka H, Baba H. CXCL12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis Cancer Sci 2019 110(10):3197-3203 PubMed ID: 31361379 DOI: 10.1111/cas.14151

14816 Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma Cancer Discov 2019 9(8):1064-1079 PubMed ID: 31109923 DOI: 10.1158/2159-8290.CD-19-0182

11220 You HL, Liu TT, Weng SW, Chen CH, Wei YC, Eng HL, Huang WT. Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma. Oncol Lett 2018 PubMed ID: 30250623 DOI: 10.3892/ol.2018.9284

4347 Lin HY, Tey SL, Ho Y, Chin YT, Wang K, Whang-Peng J, Shih YJ, Chen YR, Yang YN, Chen YC, Liu YC, Tang HY, Yang YS. Heteronemin Induces Anti-Proliferation in Cholangiocarcinoma Cells via Inhibiting TGF-β Pathway. Mar Drugs 2018 PubMed ID: 30563284 DOI: 10.3390/md16120489

14913 Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity Dis Model Mech 2018 11(8):dmm03305 PubMed ID: 29666220 DOI: 10.1242/dmm.033050

10290 Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Mol. Carcinog. 2017 56:2146-2157 PubMed ID: 28467612 DOI: 10.1002/mc.22671

10333 Huang G-, Liu TT, Weng SW, You HL, Wei YC, Chen CH, Eng HL, Huang WT. CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma. BMC Cancer 2017 17:395 PubMed ID: 28576144 DOI: 10.1186/s12885-017-3389-z

10501 Kushibiki T, Noji T, Ebihara Y, Hontani K, Ono M, Kuwabara S, Nakamura T, Tsuchikawa T, Okamura K, Ishizuka M, Hirano S. 5-Aminolevulinic-acid-mediated Photodynamic Diagnosis Enhances the Detection of Peritoneal Metastases in Biliary Tract Cancer in Mice. In Vivo 2017 31:905-908 PubMed ID: 28882957 DOI: 10.21873/invivo.11145

9871 Hoshino H, Ohta M, Ito M, Uchimura K, Sakai Y, Uehara T, Low S, Fukushima M, Kobayashi M. Apical membrane expression of distinct sulfated glycans represents a novel marker of cholangiolocellular carcinoma. Lab. Invest. 2016 96:1246-1255 PubMed ID: 27748735 DOI: 10.1038/labinvest.2016.104

3735 Saha SK et al Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov 2016 6(7):727-39 PubMed ID: 27231123 DOI: 10.1158/2159-8290.CD-15-1442

5025 Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Cancer Sci 2015 106(9):1153-62 PubMed ID: 26132727 DOI: 10.1111/cas.12732

9170 Sheng-Huei Yang 1, Hung-Yun Lin, Vincent H S Chang, Chien-Chung Chen, Yun-Ru Liu, Jinghan Wang, Keqiang Zhang, Xiaoqing Jiang, Yun Yen Lovastatin Overcomes Gefitinib Resistance Through TNF-α Signaling in Human Cholangiocarcinomas With Different LKB1 Statuses in Vitro and in Vivo Oncotarget 2015 6 (27), 23857-73 PubMed ID: 26160843 DOI: 10.18632/oncotarget.4408

15203 Wang J, Zhang K, Wang J, Wu X, Liu X, Li B, Zhu Y, Yu Y, Cheng Q, Hu Z, Guo C, Hu S, Mu B, Tsai CH, Li J, Smith L, Yang L, Liu Q, Chu P, Chang V, Zhang B, Wu M, Jiang X, Yen Y. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma Oncotarget 2015 6(22):18905-20 PubMed ID: 26056085 DOI: 10.18632/oncotarget.4305

12541 Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T. ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma Hepatol Res 2014 44(14):E320-34 PubMed ID: 24552196 DOI: 10.1111/hepr.12312

18596 Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, Kikuchi K, Yamada G, Suzuki K, Honda J, Wilson-Morifuji M, Araki N, Eto M, Baba H, Imamura T. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88) Clin Cancer Res 2013 19(8):2004-13 PubMed ID: 23287562 DOI: 10.1158/1078-0432.CCR-12-1204

12544 Kumagai A, Fukushima J, Takikawa H, Fukuda T, Fukusato T. Enhanced expression of farnesoid X receptor in human hepatocellular carcinoma Hepatol Res 2013 43(9):959-69 PubMed ID: 23369163 DOI: 10.1111/hepr.12047

14852 Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors Gastroenterology 2012 142(4):1021-1031.e15 PubMed ID: 22178589 DOI: 10.1053/j.gastro.2011.12.005

8365 Ishii T, Yasuchika K, Suemori H, Nakatsuji N, Ikai I, Uemoto S. Alpha-fetoprotein producing cells act as cancer progenitor cells in human cholangiocarcinoma. Cancer Lett. 2010 294:25-34 PubMed ID: 20149523 DOI: 10.1016/j.canlet.2010.01.019

19310 Takayama Y, Kokuryo T, Yokoyama Y, Ito S, Nagino M, Hamaguchi M, Senga T. Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis Cancer Lett 2010 296(1):27-34 PubMed ID: 20381954 DOI: 10.1016/j.canlet.2010.03.011

6410 Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y. Is parainfluenza virus a threatening virus for human cancer cell lines? Hum Cell 2009 22(3):81-4 PubMed ID: 19624309 DOI: 10.1111/j.1749-0774.2009.00071.x

18314 Tanaka Y, Kanai F, Tada M, Tateishi R, Sanada M, Nannya Y, Ohta M, Asaoka Y, Seto M, Shiina S, Yoshida H, Kawabe T, Yokosuka O, Ogawa S, Omata M. Gain of GRHL2 is associated with early recurrence of hepatocellular carcinoma J Hepatol 2008 49(5):746-57. PubMed ID: 18752864 DOI: 10.1016/j.jhep.2008.06.019

18693 Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 2008 135(4):1358-1368 PubMed ID: 18692501 DOI: 10.1053/j.gastro.2008.06.082

3575 Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008 47(3):888-96 PubMed ID: 18306229 DOI: 10.1002/hep.22125

3335 Yoshino K, Iimura E, Saijo K, Iwase S, Fukami K, Ohno T, Obata Y, Nakamura Y. Essential role for gene profiling analysis in the authentication of human cell lines. Hum Cell 2006 19(1):43-8 PubMed ID: 16643607 DOI: 10.1111/j.1749-0774.2005.00007.x

3077 Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther 2005 4:399-412 PubMed ID: 15767549 DOI: 10.1158/1535-7163.MCT-04-0234

3334 Obama, Kazutaka, Ura, Katsuaki, Satoh, Seiji, Nakamura, Yusuke, Furukawa, Yoichi Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma Oncol Res 2005 14:701-706 PubMed ID: 16077978

3346 Yokoo, Hideki, Kondo, Tadashi, Fujii, Kazuyasu, Yamada, Tesshi, Todo, Satoru, Hirohashi, Setsuo Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology 2004 40:609-17 PubMed ID: 15349899 DOI: 10.1002/hep.20372

3703 Sanada T, Yokoi S, Arii S, Yasui K, Imoto I, Inazawa J. Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci 2004 95(12):969-76 PubMed ID: 15596046 DOI: 10.1111/j.1349-7006.2004.tb03185.x

15587 Tanaka S, Iwai M, Harada Y, Morikawa T, Muramatsu A, Mori T, Okanoue T, Kashima K, Maruyama-Tabata H, Hirai H, Satoh E, Imanishi J, Mazda O. Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter Cancer Gene Ther 2000 7(9):1241-50 PubMed ID: 11023196 DOI: 10.1038/sj.cgt.7700219